Virtualizing clinical trials and COVID-19: Why digitization and connectivity are more important tha…

As the COVID-19 pandemic persists, every industry is working to pivot and adapt. In many respects, an effective vaccine will mean a return to business as usual. In health care and life sciences, it will not, nor should it.

Among the wake-up calls this coronavirus has sounded is the need to transform the way we conduct clinical trials and use the resulting data. The pandemic has exposed limitations in the clinical trial process that have had repercussions not only in the development of drugs, but also in how we might have been better prepared to face this pandemic head on.